-
1
-
-
84855792427
-
Cancer statistics, 2012
-
Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
80053111637
-
Approach to the treatment of multiple myeloma: a clash of philosophies
-
Rajkumar S.V., Gahrton G., Bergsagel P.L. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011, 118:3205-3211.
-
(2011)
Blood
, vol.118
, pp. 3205-3211
-
-
Rajkumar, S.V.1
Gahrton, G.2
Bergsagel, P.L.3
-
3
-
-
33847369790
-
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement
-
Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341.
-
(2007)
Mayo Clin Proc
, vol.82
, pp. 323-341
-
-
Dispenzieri, A.1
Rajkumar, S.V.2
Gertz, M.A.3
-
4
-
-
10744223381
-
Genetics and cytogenetics of multiple myeloma: a workshop report
-
Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
-
(2004)
Cancer Res
, vol.64
, pp. 1546-1558
-
-
Fonseca, R.1
Barlogie, B.2
Bataille, R.3
-
5
-
-
79956039754
-
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
-
Munshi N.C., Anderson K.C., Berqsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
-
(2011)
Blood
, vol.117
, pp. 4696-4700
-
-
Munshi, N.C.1
Anderson, K.C.2
Berqsagel, P.L.3
-
6
-
-
72949085546
-
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
-
Kumar S.K., Mikhael J.R., Buadi F.K., et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84:1095-1110.
-
(2009)
Mayo Clin Proc
, vol.84
, pp. 1095-1110
-
-
Kumar, S.K.1
Mikhael, J.R.2
Buadi, F.K.3
-
7
-
-
33847197966
-
Apractical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
-
Stewart A.K., Bergsagel P.L., Greipp P.R., et al. Apractical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21:529-534.
-
(2007)
Leukemia
, vol.21
, pp. 529-534
-
-
Stewart, A.K.1
Bergsagel, P.L.2
Greipp, P.R.3
-
8
-
-
84055222501
-
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
-
Rajkumar S.V. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:78-88.
-
(2012)
Am J Hematol
, vol.87
, pp. 78-88
-
-
Rajkumar, S.V.1
-
9
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEngl J Med 2008, 359:906-917.
-
(2008)
NEngl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
10
-
-
84856278440
-
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
-
Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
-
(2012)
Blood
, vol.119
, pp. 940-948
-
-
Neben, K.1
Lokhorst, H.M.2
Jauch, A.3
-
11
-
-
78049501226
-
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
-
Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). JClin Oncol 2010, 28:4630-4634.
-
(2010)
JClin Oncol
, vol.28
, pp. 4630-4634
-
-
Avet-Loiseau, H.1
Leleu, X.2
Roussel, M.3
-
12
-
-
0343355828
-
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
-
Avet-Loiseau H., Li J.Y., Facon T., et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998, 58:5640-5645.
-
(1998)
Cancer Res
, vol.58
, pp. 5640-5645
-
-
Avet-Loiseau, H.1
Li, J.Y.2
Facon, T.3
-
13
-
-
0037092981
-
Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients
-
Fonseca R., Blood E.A., Oken M.M., et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
-
(2002)
Blood
, vol.99
, pp. 3735-3741
-
-
Fonseca, R.1
Blood, E.A.2
Oken, M.M.3
-
14
-
-
0343049149
-
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
-
Königsberg R., Zojer N., Ackermann J., et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. JClin Oncol 2000, 18:804-812.
-
(2000)
JClin Oncol
, vol.18
, pp. 804-812
-
-
Königsberg, R.1
Zojer, N.2
Ackermann, J.3
-
15
-
-
0037441892
-
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
-
Avet-Loiseau H., Garand R., Lodé L., et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003, 101:1570-1571.
-
(2003)
Blood
, vol.101
, pp. 1570-1571
-
-
Avet-Loiseau, H.1
Garand, R.2
Lodé, L.3
-
17
-
-
0142151221
-
T(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
-
Garand R., Avet-Loiseau H., Accard F., et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
-
(2003)
Leukemia
, vol.17
, pp. 2032-2035
-
-
Garand, R.1
Avet-Loiseau, H.2
Accard, F.3
-
18
-
-
0034502263
-
The (11;14)(q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study
-
Hoyer J.D., Hanson C.A., Fonseca R., et al. The (11;14)(q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study. Am J Clin Pathol 2000, 113:831-837.
-
(2000)
Am J Clin Pathol
, vol.113
, pp. 831-837
-
-
Hoyer, J.D.1
Hanson, C.A.2
Fonseca, R.3
-
19
-
-
0042744766
-
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
-
Robillard N., Avet-Loiseau H., Garand R., et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003, 102:1070-1071.
-
(2003)
Blood
, vol.102
, pp. 1070-1071
-
-
Robillard, N.1
Avet-Loiseau, H.2
Garand, R.3
-
20
-
-
27744568383
-
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
-
Dewald G.W., Therneau T., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558.
-
(2005)
Blood
, vol.106
, pp. 3553-3558
-
-
Dewald, G.W.1
Therneau, T.2
Larson, D.3
-
21
-
-
0036721371
-
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
-
Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583.
-
(2002)
Blood
, vol.100
, pp. 1579-1583
-
-
Moreau, P.1
Facon, T.2
Leleu, X.3
-
22
-
-
0033567902
-
The addition of interferon or high-dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486
-
Oken M.M., Leong T., Lenhard R.E., et al. The addition of interferon or high-dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999, 86:957-968.
-
(1999)
Cancer
, vol.86
, pp. 957-968
-
-
Oken, M.M.1
Leong, T.2
Lenhard, R.E.3
-
23
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
-
(2006)
Leukemia
, vol.20
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
-
24
-
-
79955977910
-
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
-
Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
-
(2011)
Blood
, vol.117
, pp. 4691-4695
-
-
Rajkumar, S.V.1
Harousseau, J.L.2
Durie, B.3
-
25
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
-
(1958)
JAm Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
26
-
-
27144441760
-
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
-
Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
-
(2005)
Blood
, vol.106
, pp. 2837-2840
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
-
27
-
-
33847378314
-
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
-
Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
-
(2007)
Blood
, vol.109
, pp. 3489-3495
-
-
Avet-Loiseau, H.1
Attal, M.2
Moreau, P.3
-
28
-
-
84880447379
-
Impact of non high-risk chromosomal abnormalities on the outcome of autologous hematopoietic stem cell transplantation in multiple myeloma [abstract]
-
ASH Annual Meeting Abstracts
-
Ahmed S., Lin H., Baladandayuthapani V., et al. Impact of non high-risk chromosomal abnormalities on the outcome of autologous hematopoietic stem cell transplantation in multiple myeloma [abstract]. Blood 2011, 118:333. ASH Annual Meeting Abstracts.
-
(2011)
Blood
, vol.118
, pp. 333
-
-
Ahmed, S.1
Lin, H.2
Baladandayuthapani, V.3
-
29
-
-
77953632707
-
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
-
Nair B., van Rhee F., Shauqhnessy J.D., et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
-
(2010)
Blood
, vol.115
, pp. 4168-4173
-
-
Nair, B.1
van Rhee, F.2
Shauqhnessy, J.D.3
-
30
-
-
33847312216
-
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
-
Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007, 39:279-283.
-
(2007)
Bone Marrow Transplant
, vol.39
, pp. 279-283
-
-
Qazilbash, M.H.1
Saliba, R.M.2
Hosing, C.3
-
31
-
-
84860219808
-
Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
-
Sharma M., Khan H., Thall P.F., et al. Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012, 118:2507-2515.
-
(2012)
Cancer
, vol.118
, pp. 2507-2515
-
-
Sharma, M.1
Khan, H.2
Thall, P.F.3
-
32
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp P.R., Miguel J.S., Durie B.G., et al. International staging system for multiple myeloma. JClin Oncol 2005, 23:3412-3420.
-
(2005)
JClin Oncol
, vol.23
, pp. 3412-3420
-
-
Greipp, P.R.1
Miguel, J.S.2
Durie, B.G.3
-
33
-
-
33645706760
-
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients
-
O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006, 37:731-737.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 731-737
-
-
O'Shea, D.1
Giles, C.2
Terpos, E.3
|